Gyre Therapeutics (GYRE) Proxy filing summary

Voting matters and shareholder proposals

• Election of two Class II Directors, David M. Epstein, Ph.D. and Dan Weng, M.D., for terms expiring in 2029.

• Advisory vote to approve the compensation of named executive officers.

• Ratification of Grant Thornton Zhitong Certified Public Accountants LLP as independent auditor for the year ending December 31, 2026.

• Approval of issuance of common stock upon conversion of Series B Convertible Preferred Stock, in accordance with Nasdaq Listing Rule 5635(a).

• Other business may be addressed as appropriate during the meeting or any adjournment.

Board of directors and corporate governance

• Board recommends voting in favor of all proposals, including director elections and compensation matters.

Executive compensation and say-on-pay

• Advisory vote scheduled to approve executive compensation on a non-binding basis.